Clinically, LEF1 -inactivating mutations show a favorable trend towards overall survival in pediatric patients with T-ALL, which suggests that this molecular subtype of the disease may be more responsive than other subtypes to salvage therapy for relapsed T-ALL [ 87 ]. 3.8.
← all excerpts
New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update.
1
—
—